蛋白质稳定性分析市场 - 全球产业规模、份额、趋势、机会及预测（按产品、技术、最终用途、地区和竞争格局划分，2021-2031年）

全球蛋白质稳定性分析市场预计将从 2025 年的 33.5 亿美元成长到 2031 年的 62.7 亿美元，复合年增长率达到 11.01%。

此领域涵盖用于评估蛋白质治疗药物在不同环境条件下结构完整性的调查方法。推动该市场发展的关键因素是製药业日益关注复杂的生物製药，这些製剂需要进行严格的稳定性分析，以确保药物安全并符合监管要求。此外，对创新的大量投资也进一步刺激了这项需求。根据欧洲製药工业协会联合会 (EFPIA) 预测，到 2024 年，欧洲製药业预计将在研发方面投入约 550 亿欧元。这些投资凸显了稳定性分析在降低高价值药物开发专案风险方面发挥的关键作用。

然而，由于专业分析设备的高昂实施成本，市场面临许多障碍。先进技术所需的大量资本投入限制了预算有限的中小型生物技术公司的进入。因此，此财务壁垒阻碍了综合检测解决方案的广泛应用，并限制了市场扩张。

市场驱动因素

生物製药和生物製药的快速发展是全球蛋白质稳定性分析市场的主要驱动力。随着製药业将重心从小分子药物转向单株抗体和重组蛋白等复杂的大分子治疗药物，对稳健的稳定性测试至关重要，以防止药物在储存和运输过程中发生聚集，并确保其疗效。越来越多的新生物製药进入监管审批流程，也直接推动了这个趋势。根据美国食品药物管理局(FDA) 于 2024 年 1 月发布的《2023 年新药核准情况报告》，该机构预计将在 2023 年核准55 种新疗法，较上年度的37 种显着增加。如此大量的新药上市需要进行严格的分析测试以满足安全通讯协定，从而扩大了稳定性分析服务和设备的市场需求。

同时，製药和生物技术公司不断增加的研发投入为先进稳定性测试解决方案的实施提供了必要的资金。高价值药物开发专案需要先进的分析技术来评估蛋白质在压力条件下的完整性，而各公司也正为这些品质保证措施分配大量预算。例如，根据强生公司于2024年1月发布的「2023财年全年业绩」新闻稿，该公司报告称，该财年的研发投入创下151亿美元的纪录。如此庞大的支出反映了整个产业财务实力推动技术创新的趋势。此外，区域成长也凸显了该产业强劲的财务状况。根据瑞士生物技术协会于2024年4月发布的“2024年瑞士生物技术报告”，预计仅瑞士生物技术产业在2023年就将创造73亿瑞士法郎的创纪录收入，这证实了全球拥有大量资源来支持蛋白质稳定性分析等关键开发步骤。

市场挑战

专业分析设备高昂的实施成本是全球蛋白质稳定性分析市场扩张的一大障碍。先进的稳定性分析需要精密的硬件，这需要大量的资本投入，从而对小规模的市场参与企业构成了很高的进入门槛。这种财务负担对新兴生技公司和学术研究机构的影响尤其显着，因为它们的预算往往有限。因此，这些机构被迫推迟购买关键的内部测试设备，阻碍了先进稳定性分析解决方案的广泛应用，并减缓了整体市场收入的成长。

生技产业面临的动盪投资环境进一步加剧了这种经济压力。根据生技创新组织（BIO）的数据显示，2025年第二季新兴生技公司的Start-Ups资金大幅下降至9亿美元，远低于第一季的26亿美元。资金的日益紧缩迫使中小企业优先考虑紧迫的临床开发成本，而非基础设施投资，这直接降低了它们购买高价值稳定性分析系统的能力。因此，市场面临着来自这一重要客户群的需求下降，限制了技术整合的广泛应用，并阻碍了产业发展。

市场趋势

将人工智慧融入预测稳定性建模正在从根本上改变生物製药公司评估候选药物的方式。借助先进的机器学习演算法，研究人员现在可以在物理测试开始之前，透过电脑模拟准确预测蛋白质降解途径和聚集风险。这项能力显着减少了早期开发所需的资源，并且能够快速优先筛选出高度稳定的分子。业界对这项技术的投入也反映在定向资本注入。根据AI Proteins公司2025年11月发布的题为「AI Proteins完成A轮融资4150万美元，推进全新微型蛋白开发作为新型治疗方法」的新闻稿，该公司获得了4150万美元的资金筹措，用于加速其人工智能驱动的稳定治疗性微型蛋白设计平台。此类投资凸显了向计算方法转变的趋势，旨在最大限度地降低后期临床试验的失败率。

同时，随着自动化实验室工作流程的实施，稳定性测试的实际操作效率也日益提高。实验室正在部署机器人液体处理系统和自动盘式分析仪，以处理复杂生物分析所需的大量样本，从而消除人为误差并提高数据可重复性。这种从手动流程向自动化流程的转变对于维持现代研发中心的高通量能力至关重要。近期企业策略也显着体现了这项基础设施的扩展。根据阿斯特捷利康2024年11月发布的题为「投资35亿美元用于美国研发和生产」的新闻稿，该公司宣布将投资35亿美元用于扩大其研发规模，包括整合先进的自动化技术。这些自动化系统将确保蛋白质稳定性分析能够跟上药物研发加速发展的脚步。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球蛋白质稳定性分析市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（试剂及检测试剂盒、设备、耗材及配件、软体）
  • 透过技术（层析法、光谱法、表面等离子体共振成像（SPRI）、差示扫描量热法（DSC）、差示扫描萤光（DSF）及其他）
  • 透过申请（製药和生物技术公司、受託研究机构(CRO)、学术机构、研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美蛋白质稳定性分析市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲蛋白质稳定性分析市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区蛋白质稳定性分析市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲蛋白质稳定性分析市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美蛋白质稳定分析市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球蛋白质稳定性分析市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Unchained Labs
• ProtaGene US, Inc.
• Charles River Laboratories International, Inc.
• Intas Pharmaceuticals Ltd.
• Amgen Inc.
• Neurelis, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Enzo Biochem Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Protein Stability Analysis Market is projected to expand from USD 3.35 Billion in 2025 to USD 6.27 Billion by 2031, achieving a compound annual growth rate of 11.01%. This sector encompasses analytical methodologies utilized to evaluate the structural integrity of protein therapeutics across diverse environmental conditions. A primary force driving this market is the pharmaceutical industry's deepening focus on complex biologics, which necessitates rigorous stability profiling to guarantee drug safety and adhere to regulatory mandates. This demand is bolstered by significant financial commitments to innovation; according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the pharmaceutical sector invested an estimated €55,000 million in research and development within Europe in 2024. Such investment underscores the vital role of stability analysis in mitigating risks within high-value drug development programs.

However, the market faces a substantial obstacle due to the high acquisition costs associated with specialized analytical instrumentation. The significant capital expenditure required for advanced technologies restricts accessibility for smaller biotechnology enterprises operating with limited budgets. Consequently, this financial barrier hinders the widespread adoption of comprehensive testing solutions and constrains broader market expansion.

Market Driver

The surge in biopharmaceutical and biologics development serves as a primary catalyst for the Global Protein Stability Analysis Market. As the pharmaceutical industry shifts its focus from small-molecule drugs to complex large-molecule therapeutics, such as monoclonal antibodies and recombinant proteins, the requirement for robust stability testing becomes critical to prevent aggregation and ensure efficacy during storage and transport. This trend is directly evidenced by the increasing volume of novel biological entities entering the regulatory pipeline. According to the U.S. Food and Drug Administration's 'Novel Drug Approvals for 2023' report from January 2024, the agency approved 55 novel therapeutics in 2023, a significant rise from the 37 approvals recorded in the previous year. This influx necessitates rigorous analytical testing to satisfy safety protocols, thereby expanding the market for stability analysis services and instrumentation.

Concurrently, increasing R&D investments by pharmaceutical and biotechnology companies are providing the necessary capital to adopt advanced stability testing solutions. High-value drug development programs require sophisticated analytical technologies to assess protein integrity under stress conditions, prompting companies to allocate substantial budgets toward these quality assurance measures. For instance, according to Johnson & Johnson's 'Full Year 2023 Results' press release in January 2024, the company reported a record research and development investment of $15.1 billion for the fiscal year. This scale of spending reflects a broader industry pattern where financial health drives technical innovation. Furthermore, the sector's robust financial footing is highlighted by regional growth; according to the Swiss Biotech Association's 'Swiss Biotech Report 2024' from April 2024, the Swiss biotechnology industry alone generated a record revenue of CHF 7.3 billion in 2023, underscoring the massive global resources available to support essential development phases like protein stability analysis.

Market Challenge

The high acquisition costs associated with specialized analytical instrumentation constitute a significant impediment to the expansion of the Global Protein Stability Analysis Market. Advanced stability profiling requires precise hardware that commands substantial capital expenditure, creating a steep barrier to entry for smaller market participants. This financial burden disproportionately affects emerging biotechnology companies and academic research institutions, which often operate under restricted budgets. Consequently, these organizations are frequently compelled to defer the purchase of essential in-house testing equipment, thereby stifling the broader adoption of advanced stability analysis solutions and slowing overall market revenue growth.

This economic pressure is significantly exacerbated by the volatile investment climate currently facing the biotechnology sector. According to the Biotechnology Innovation Organization (BIO), in 2025, startup funding for emerging biotech companies declined sharply to $900 million in the second quarter, down from $2.6 billion in the first quarter. Such a contraction in available capital forces smaller enterprises to prioritize immediate clinical development expenses over infrastructure investments, directly reducing their capacity to procure high-value stability analysis systems. As a result, the market faces reduced demand from this critical customer segment, limiting the potential for widespread technological integration and hampering sector progress.

Market Trends

The Integration of Artificial Intelligence for Predictive Stability Modeling is fundamentally reshaping how biopharmaceutical companies assess drug candidates. By leveraging advanced machine learning algorithms, researchers can now accurately forecast protein degradation pathways and aggregation risks in silico before physical testing begins. This capability significantly reduces the resources required for early-stage development, allowing for the rapid prioritization of stable molecules. The sector's commitment to this technology is evident in targeted capital injections; according to AI Proteins' press release 'AI Proteins Raises $41.5M Series A Financing to Advance De Novo Miniproteins as a New Therapeutic Modality' in November 2025, the biotechnology company secured $41.5 million in funding specifically to accelerate its AI-driven platform for designing stable therapeutic miniproteins. Such investment underscores the shift toward computational methods that minimize failure rates in late-stage studies.

Concurrently, the Implementation of Automated Laboratory Workflows is streamlining the physical execution of stability testing. Laboratories are deploying robotic liquid handling systems and automated plate readers to manage the high volume of samples required for complex biologic profiling, thereby eliminating human error and enhancing data reproducibility. This transition from manual to automated processes is critical for maintaining high-throughput capabilities in modern R&D centers. This infrastructure expansion is highlighted by recent corporate strategies; according to AstraZeneca's 'AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States' press release in November 2024, the company announced a $3.5 billion capital investment focused on expanding its research footprint, which includes the integration of advanced automation technologies. These automated systems ensure that protein stability analysis keeps pace with the accelerating speed of drug discovery.

Key Market Players

• Unchained Labs
• ProtaGene US, Inc.
• Charles River Laboratories International, Inc.
• Intas Pharmaceuticals Ltd.
• Amgen Inc.
• Neurelis, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Enzo Biochem Inc.

Report Scope

In this report, the Global Protein Stability Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Stability Analysis Market, By Product

• Reagents and Assay Kits
• Instruments
• Consumable and Accessories
• Software

Protein Stability Analysis Market, By Technique

• Chromatography
• Spectroscopy
• Surface Plasma Resonance Imaging (SPRI)
• Differential Scanning Calorimetry (DSC)
• Differential Scanning Fluorimetry (DSF)
• Others

Protein Stability Analysis Market, By End Use

• Pharmaceutical and Biotechnology Companies
• Contract Research Organization
• Academic
• Research Institutes

Protein Stability Analysis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Stability Analysis Market.

Available Customizations:

Global Protein Stability Analysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Stability Analysis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Reagents and Assay Kits, Instruments, Consumable and Accessories, Software)
  • 5.2.2. By Technique (Chromatography, Spectroscopy, Surface Plasma Resonance Imaging (SPRI), Differential Scanning Calorimetry (DSC), Differential Scanning Fluorimetry (DSF), Others)
  • 5.2.3. By End Use (Pharmaceutical and Biotechnology Companies, Contract Research Organization, Academic, Research Institutes)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Protein Stability Analysis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technique
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protein Stability Analysis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada Protein Stability Analysis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico Protein Stability Analysis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By End Use

7. Europe Protein Stability Analysis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technique
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protein Stability Analysis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By End Use
  • 7.3.2. France Protein Stability Analysis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom Protein Stability Analysis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy Protein Stability Analysis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain Protein Stability Analysis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By End Use

8. Asia Pacific Protein Stability Analysis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technique
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protein Stability Analysis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By End Use
  • 8.3.2. India Protein Stability Analysis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan Protein Stability Analysis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea Protein Stability Analysis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia Protein Stability Analysis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By End Use

9. Middle East & Africa Protein Stability Analysis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technique
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protein Stability Analysis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE Protein Stability Analysis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa Protein Stability Analysis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By End Use

10. South America Protein Stability Analysis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technique
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protein Stability Analysis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia Protein Stability Analysis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina Protein Stability Analysis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protein Stability Analysis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Unchained Labs
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ProtaGene US, Inc.
• 15.3. Charles River Laboratories International, Inc.
• 15.4. Intas Pharmaceuticals Ltd.
• 15.5. Amgen Inc.
• 15.6. Neurelis, Inc.
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Agilent Technologies, Inc.
• 15.9. PerkinElmer Inc.
• 15.10. Enzo Biochem Inc.

16. Strategic Recommendations

17. About Us & Disclaimer